title: The development and evaluation of stimulant treatment programmes.
abstract: OBJECTIVE
  To summarize the recent literature (1st January 2014-1st February 2015) on stimulant treatment programme evaluations, and highlight key areas for future programme development.
  
  
  RESULTS
  Advances have been made in addressing both sexual risks and stimulant use among gay and bisexual men in the United States, and in adapting evidence-based resource-intense interventions to real-world settings. Programme outcome measures increasingly include changes in substance use as well as health and wellbeing indicators and measures of risk.
  
  
  CONCLUSIONS
  Future programme directions include: expansion of the psychosocial repertoire to include narrative and mindfulness-based therapies; web-based programme delivery; sex-sensitive programming to attract and retain women; comprehensive programming to address coexisting mental and physical illness and polysubstance use (including tobacco smoking); and improving accessibility to promote early intervention. Comparability of evaluation data can be improved by developing standardized tools particularly for measuring change in sexual-risk behavior. The use of new statistical techniques can address the lack of comparison populations.
authors.affiliation: aSt Vincent's Hospital Clinical School, Faculty of Medicine, UNSW bSt Vincent's Hospital, Sydney cNational Drug and Alcohol Research Centre, UNSW, Sydney, Australia.
authors.forename: Nadine
authors.initials: N
authors.lastname: Ezard
authors.forename: Sianne
authors.initials: S
authors.lastname: Hodge
authors.forename: Kate
authors.initials: K
authors.lastname: Dolan
mesh_terms: D001727:Bisexuality; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D005260:Female; D006297:Health Services Accessibility / Q000639:trends; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D016730:Program Development; D015397:Program Evaluation; D012309:Risk-Taking; D055502:Secondary Prevention / Q000639:trends; D019966:Substance-Related Disorders / Q000628:therapy*; D014481:United States; D047568:Unsafe Sex / Q000517:prevention & control
chemical_list: D000697:Central Nervous System Stimulants